thank stand welcome second quarter earn conference call time participant line listen mode speaker presentation question answer session operator instruction would like turn call first participant today vice president investor relation please ahead vice president investor relation thank good morning everyone welcome perkinelmer second quarter earn conference call speak morning quite bite give today excite announcement addition earlier expect release second quarter result call today president chief executive officer senior vice president chief financial officer gene founder chief executive officer receive copy earn press release slide presentation relate slide presentation press release find copy investor section website perkinelmer please note call webcast archive perkinelmer website begin would like turn slide remind everyone safe harbor statement outline earn press release issue earlier morning also file statement comment make call forward look statement include necessarily limit financial projection statement company plan objective expectation intention matter involve certain risk uncertainty company actual result differ significantly project suggest forward look statement variety factor discuss detail file forward look statement make today represent view today disclaim obligation update forward look statement future even estimate change rely today forward look statement represent view date today call refer certain financial measure reconciliation financial measure plan call directly comparable measure available attachment earn press release extent financial measure call reconcile attachment promptly turn president chief executive officer president chief executive build analyst today represent another milestone transformation perkinelmer addition expand presence attractive high growth antibody cytokine market enhance content development capability across perkinelmer detection technology transform scale commerce scale overnight personally thrill work gene forward excite impact combine company scientific innovation culturally combination natural mutual focus customer innovation internal cross functional collaboration global leader innovative antibody lead position several attractive market include image proteogenomics multiplex assay process combination enable create global platform research reagent share today fundamentally change trajectory organization combine perkinelmer empower customer clinical discovery look identify develop optimize novel therapeutic turn support bring right therapeutic market faster fundamentally bring perkinelmer family enhance core right biopharma academia financial perspective expect excite combination lead faster growth stronger margin rapid product product innovation strategically align structure ensure success touch specific want provide perspective deal mean company overall slightly billion total consideration combine company expect nearly million revenue next year expect grow teen exclude expect synergy accelerate organic growth profile base expect favorable margin result several basis point increase overall company operate profit rate give dynamic expect deal provide significant immediate accretion adjust expect compound future year morning dive fully want give gene founder opportunity introduce share think excitement combination opportunity bring perspective gene gene founder chief executive officer perkinelmer thank thrill join perkinelmer carry company mission enable legendary discovery research cure past year build lead global innovator reagent consumables life science several disruptive technology platform large diversify product portfolio target variety category include cell analysis proteogenomics rapidly grow attractive application today customer across country demonstrate strong brand leadership growth portfolio offer high quality efficient manufacture strong commercial supply chain infrastructure always dedicate develop innovative product deliver high quality value customer worldwide industry standard customer service believe still start massive opportunity ahead product portfolio position capitalize rapidly grow area life science combine perkinelmer able employ technology capability global infrastructure become global leader reagent consumables look forward work together perkinelmer benefit life science patient help president chief executive gene want formally welcome perkinelmer family discuss last month know excite mean company combine business able together year come slide tell world class organization propel strong bottom company achieve lead market position number attractive high growth market antibody development flow cytometry reagent proteogenomics magnetic cell separation recombinant protein cytokine growth factor represent total addressable market approximately billion area expertise span upstream research immunology oncology stem cell research neuroscience infectious disease downstream bioprocessing employee across pacific serve customer country company also stellar track record product introduction launch annually exist market revenue recur nature world class manufacture distribution capability translate attractive incremental margin profile finally come recognize perkinelmer share fierce passion commitment focus customer mission help scientist accelerate research discovery provide highest quality product outstanding value along superior customer service technical support succinctly passionate make mark world legendary right push boundary biological understand slide headquarter reside beautiful expansive state campus today four build campus become global center excellence perkinelmer reagent content development serve entire life science portfolio combine company expertise create even nimble powerful reagent innovation engine enable accelerate pace product introduction exist market high growth area focus company cell gene therapy single cell analysis example able combine lead position proteogenomics perkinelmer recognize upstream discovery identification peptide measure downstream drug target study support customer high throughput test potentially single cell level technology also believe diagnostics business benefit faster antibody base assay development lower house access exist antibody library also expand global product development expert touch bite later expect combine research region franchise leverage perkinelmer global scale strong customer relationship enable even greater commercial success leverage company core strength people combine innovation engine perkinelmer geographic channel breadth along focus research reagent operational excellence elevate already strong franchise company mind customer ultimately result even faster growth would expect combination result million annual synergy revenue synergy year five slide nearly million expect revenue next year combine exist million research reagent business perkinelmer largest antibody research reagent business industry annual revenue approximately million healthy market growth share gain product innovation margin high growth area expect combine business grow double digit rate annually foreseeable future like provide detail combination mean perkinelmer financial perspective share perspective strategic alignment combine company senior vice president chief financial echo sentiment great meet gene today equally excite impact improve outcome stakeholder addition accelerate transformation perkinelmer position deliver even stronger financial performance bottom year ahead recently tell investor last month outline slide expect exist perkinelmer business grow organically year single high single digit range longer term deliver strategic imperative give size expect growth combine revenue synergy expect start contribute year combine company grow least basis point faster annually previous outlook near long term know expect close year start positively impact organic growth base since revenue entirely reagent consumables perkinelmer around revenue recur nature basis point level give accretive margin profile expect overall company operate margin increase approximately basis point current level expect previously communicate goal basis point annual operate margin expansion continue improvement exist business largely come gross margin line operational excellence initiative highlight recent analyst meet expect rapid line growth provide opportunity opex line continue reinvest heavily company throughout history today business commerce channel plan leverage horizon platform scale ecosystem approximately million annualized life science research revenue opportunity rapidly scale market synergy across portfolio finally nearly revenue come biopharma academic market continue invest organically cyclical business expect perkinelmer total revenue would come life science diagnostic business term structure deal think advantageous many angle walk slide first largest deal history perkinelmer tremendous skill life science franchise able combine business manage leverage also closely align interest exist shareholder clearly potential come year combine organization fully underwrite bridge finance already place seek take appropriate permanent debt come month excite exist concentrate shareholder base make slightly perkinelmer overall ownership along gene shareholder feel structure provide near term cash compensation great business build nearly decade maintain significant interest participate future success combine business forward agree bright follow completion deal expect leverage slightly four time first part plan delever three time debt adjust within month commit fully expect maintain investment grade addition promise future believe company hold innovation customer employee opportunity perspective expect overall company faster line growth enhance margin profile deliver incremental adjust accretion first year post close greater accretion second year shareholder high single digit return invest capital year think combination right button strategic cultural financial future innovation perspective excite future perkinelmer like turn back final comment combination president chief executive better know entrepreneurial think find join perkinelmer create true antibody life science reagent powerhouse scale able accelerate scientific advancement product innovation across company around world believe combination position perkinelmer best class preclinical life science franchise uniquely position empower external partner deliver truly legendary discovery come year power company employee asset come together roof expect heighten pace collaborative innovation combine broad commercial reach lead faster overall growth perkinelmer elevate margin profile immediate significant accretion even importantly join force perkinelmer complement value life science business join company last year horizon discovery recently bioscience biotech excite future like turn call back result update guidance remainder year senior vice president chief financial perform extremely second quarter business market return growth versus level quarter order growth exceed strong revenue growth third quarter revenue come solidly previous expectation despite decline sequentially expect second quarter adjust revenue grow compare last year billion include foreign exchange acquisition tailwind organic revenue grow percentage point better previously communicate revenue grow organically high teen rate expect relate product service contribute million quarter solidly previous million expectation demand test extraction solution fall degree previously expect especially area lower vaccination rate increase presence variant part southeast turnkey test solution state unite perform line expectation result core product generate approximately million revenue quarter business diagnostics represent total sale increase organically organic growth product strength immunodiagnostics business lead drive sale business continue rebound strongly reproductive health business able offset continue birth rate pressure post double digit growth year year single digit growth year average basis apply genomics business strong rebound relate demand double versus last year offset expect decline relate product discovery analytical solution represent total sale increase organically broad base growth across life science food apply geographic perspective organic growth extremely balance three region grow similarly also grow high range operationally another strong quarter leverage significant revenue growth experience adjust operate margin expand basis point drive volume leverage business productivity program adjust earn share second quarter increase relative second quarter guidance look driver within segment start discovery analytical solution segment grow organically versus period last year market experience balance double digit growth segment life science nearly flat comp second quarter drive strong growth pharma biotech academic government market discovery grow analytical grow year year late quarter also close acquisition excite innovative cell count technology life science platform food post strong growth second quarter fairly easy year comparison food safety business continue rebound grow compare second quarter last year cannabis activity begin return contribute growth expect level impact continue improve remainder year industrial environmental safety grow line overall segment balance performance geographic perspective strengthen spectroscopy chromatography notable demand semiconductor customer turn diagnostics mention earlier organic growth increase double digit growth triple digit growth larger service business compare year revenue year year diagnostic business still grow approximately compare second quarter last year post double digit growth year average basis immunodiagnostics franchise lead post year year growth quarter incremental revenue join nearly growth revenue lead demand slow test come serology demand continue remain consistent last quarter though significantly year period initial rush demand make market also begin nice relate demand outside unite state first spot discovery measure cell immune response finally shortly quarter close acquisition system wait collaboration strong franchise near term maybe even importantly longer term apply genomics business organic revenue grow nearly overall despite relate demand drop meaningfully demand double compare year period strong growth apply genomics broad base include contribution newer external partnership recent product introduction also uptick customer appear pivot back former area focus pandemic moderate perspective nice recently include support test capacity year also uptick next generation sequence demand relate additional variant continue emerge around world reproductive health franchise grow high teen negative year comparison year average basis business still grow single digit growth balance geographically quarter region post double digit growth versus second quarter last year birth rate appear remain pressure globally neonatal prenatal business still post solid growth continue geographic menu expansion business grow strongly several product introduction introduction screen continue help offset birth rate relate pressure move line item adjust interest expense second quarter approximately million adjust rate turn balance sheet finish quarter approximately billion debt million cash adjust free cash flow million quarter equate adjust free cash flow conversion rate include large payment receive later expect first week third quarter free cash flow conversion would adjust income finally exit quarter debt adjust ratio approximately time even first quarter relate guidance anticipate full year adjust revenue billion guidance assume revenue approximately billion compare prior guidance billion billion last year update account outperformance leave second half expectation unchanged expect revenue continue remain strong remainder year face quite easy year comparison quarter translate expect organic growth year previous outlook assumption account incremental lockdown relate disruption additionally anticipate benefit acquisition close benefit foreign exchange full year take account acquisition expect close anything relate bottom line expect adjust earn share assume approximately million adjust interest expense rate average dilute share count range million million share third quarter forecast adjust revenue approximately billion represent minus year year decline total company organic growth expect year year decline revenue contribution acquisition foreign exchange respectively embed guidance million relate revenue compare million year organic growth product line term adjust earn share third quarter forecast assume approximately million interest expense rate dilute share count million million share guidance detail second last page today presentation close business continue perform extremely foundational pillar highlight recent analyst excite addition feel extremely position ahead customer scientific innovation perspective opportunity company offer employee strong financial profile shareholder perspective purely reflection tremendous effort soon colleague around globe help build company today foundation significant growth future like turn back operator begin